Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy.

Doherty MK, O'Connor E, Hannon D, O'Reilly A, Yen D, Redmond M, Grogan LM, Hennessy BT, Breathnach OS, Morris PG.

Ir J Med Sci. 2018 Jun 9. doi: 10.1007/s11845-018-1839-5. [Epub ahead of print]

PMID:
29948461
2.

Brief report on the detection of the EGFR-T790M mutation in exhaled breath condensate from lung cancer patients.

Smyth RJ, Toomey SM, Sartori A, Hanrahan EO, Cuffe SD, Breathnach OS, Morgan RK, Hennessy BT.

J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30595-1. doi: 10.1016/j.jtho.2018.04.033. [Epub ahead of print]

PMID:
29751135
3.

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O'Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S.

J Clin Oncol. 2018 Apr 1;36(10):981-990. doi: 10.1200/JCO.2017.74.8301. Epub 2018 Feb 22.

PMID:
29470143
4.

Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro.

Aslan O, Cremona M, Morgan C, Cheung LW, Mills GB, Hennessy BT.

BMC Cancer. 2018 Feb 9;18(1):168. doi: 10.1186/s12885-018-4035-0.

5.

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.

Milewska M, Cremona M, Morgan C, O'Shea J, Carr A, Velanki SH, Hopkins AM, Toomey S, Madden SF, Hennessy BT, Eustace AJ.

Ther Adv Med Oncol. 2018 Jan 9;10:1758834017746040. doi: 10.1177/1758834017746040. eCollection 2018.

6.

PI3K inhibition to overcome endocrine resistance in breast cancer.

Keegan NM, Gleeson JP, Hennessy BT, Morris PG.

Expert Opin Investig Drugs. 2018 Jan;27(1):1-15. doi: 10.1080/13543784.2018.1417384. Epub 2018 Jan 6. Review.

PMID:
29252036
7.

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.

O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ.

Oncotarget. 2017 Jul 22;8(49):85120-85135. doi: 10.18632/oncotarget.19461. eCollection 2017 Oct 17.

8.

CD10-/ALDH- cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy.

Ffrench B, Gasch C, Hokamp K, Spillane C, Blackshields G, Mahgoub TM, Bates M, Kehoe L, Mooney A, Doyle R, Doyle B, O'Donnell D, Gleeson N, Hennessy BT, Stordal B, O'Riain C, Lambkin H, O'Toole S, O'Leary JJ, Gallagher MF.

Cell Death Dis. 2017 Oct 19;8(10):e3128. doi: 10.1038/cddis.2017.379.

9.

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.

Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.

10.

S100β as a serum marker in endocrine resistant breast cancer.

Charmsaz S, Hughes É, Bane FT, Tibbitts P, McIlroy M, Byrne C, Cocchiglia S, McBryan J, Hennessy BT, Dwyer RM, Kerin MJ, Hill AD, Young LS.

BMC Med. 2017 Apr 12;15(1):79. doi: 10.1186/s12916-017-0836-2.

11.

Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

Fernández ML, DiMattia GE, Dawson A, Bamford S, Anderson S, Hennessy BT, Anglesio MS, Shepherd TG, Salamanca C, Hoenisch J, Tinker A, Huntsman DG, Carey MS.

Am J Cancer Res. 2016 Oct 1;6(10):2235-2251. eCollection 2016.

12.

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.

Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ.

Oncotarget. 2016 Nov 15;7(46):75518-75525. doi: 10.18632/oncotarget.12782.

13.

BCL-2 system analysis identifies high-risk colorectal cancer patients.

Lindner AU, Salvucci M, Morgan C, Monsefi N, Resler AJ, Cremona M, Curry S, Toomey S, O'Byrne R, Bacon O, Stühler M, Flanagan L, Wilson R, Johnston PG, Salto-Tellez M, Camilleri-Broët S, McNamara DA, Kay EW, Hennessy BT, Laurent-Puig P, Van Schaeybroeck S, Prehn JHM.

Gut. 2017 Dec;66(12):2141-2148. doi: 10.1136/gutjnl-2016-312287. Epub 2016 Sep 23.

PMID:
27663504
14.

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.

Salvucci M, Würstle ML, Morgan C, Curry S, Cremona M, Lindner AU, Bacon O, Resler AJ, Murphy ÁC, O'Byrne R, Flanagan L, Dasgupta S, Rice N, Pilati C, Zink E, Schöller LM, Toomey S, Lawler M, Johnston PG, Wilson R, Camilleri-Broët S, Salto-Tellez M, McNamara DA, Kay EW, Laurent-Puig P, Van Schaeybroeck S, Hennessy BT, Longley DB, Rehm M, Prehn JH.

Clin Cancer Res. 2017 Mar 1;23(5):1200-1212. doi: 10.1158/1078-0432.CCR-16-1084. Epub 2016 Sep 20.

15.

The impact of outpatient systemic anti-cancer treatment on patient costs and work practices.

Collins DC, Coghlan M, Hennessy BT, Grogan L, Morris PG, Breathnach OS.

Ir J Med Sci. 2017 Feb;186(1):81-87. doi: 10.1007/s11845-016-1483-x. Epub 2016 Aug 6.

PMID:
27498210
16.

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT.

J Natl Cancer Inst. 2016 Jul 4;108(8). pii: djw111. doi: 10.1093/jnci/djw111. Print 2016 Aug. No abstract available.

17.

Obesity Correlation With Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast Cancer.

Osman MA, Hennessy BT.

Clin Med Insights Oncol. 2015 Nov 24;9:105-12. doi: 10.4137/CMO.S32812. eCollection 2015.

18.

Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.

Smyth L, Watson G, Walsh EM, Kelly CM, Keane M, Kennedy MJ, Grogan L, Hennessy BT, O'Reilly S, Coate LE, O'Connor M, Quinn C, Verleger K, Schoeman O, O'Reilly S, Walshe JM.

Breast Cancer Res Treat. 2015 Oct;153(3):573-82. doi: 10.1007/s10549-015-3555-4. Epub 2015 Sep 12.

PMID:
26364296
19.

PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.

Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP.

Mol Oncol. 2015 Oct;9(8):1694-703. doi: 10.1016/j.molonc.2015.04.014. Epub 2015 May 16.

20.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149.

PMID:
25746038
21.

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.

Elster N, Collins DM, Toomey S, Crown J, Eustace AJ, Hennessy BT.

Breast Cancer Res Treat. 2015 Jan;149(1):5-15. doi: 10.1007/s10549-014-3250-x. Epub 2014 Dec 27. Review.

PMID:
25542271
22.

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.

Elster N, Cremona M, Morgan C, Toomey S, Carr A, O'Grady A, Hennessy BT, Eustace AJ.

Breast Cancer Res Treat. 2015 Jan;149(2):373-83. doi: 10.1007/s10549-014-3239-5. Epub 2014 Dec 21.

PMID:
25528022
23.

BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer.

Flanagan L, Lindner AU, de Chaumont C, Kehoe J, Fay J, Bacon O, Toomey S, Huber HJ, Hennessy BT, Kay EW, McNamara DA, Prehn JH.

J Mol Med (Berl). 2015 Mar;93(3):315-26. doi: 10.1007/s00109-014-1221-7. Epub 2014 Nov 13.

PMID:
25388617
24.

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.

Madden SF, Clarke C, Stordal B, Carey MS, Broaddus R, Gallagher WM, Crown J, Mills GB, Hennessy BT.

Mol Cancer. 2014 Oct 24;13:241. doi: 10.1186/1476-4598-13-241.

25.

Immune effects of bevacizumab: killing two birds with one stone.

Elamin YY, Rafee S, Toomey S, Hennessy BT.

Cancer Microenviron. 2015 Apr;8(1):15-21. doi: 10.1007/s12307-014-0160-8. Epub 2014 Oct 18.

26.

Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer.

O'Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, Zagozdzon A, O'Connor DP, Brennan DJ, Connor K, Li J, Gonzalez-Angulo AM, Sun HD, Pu JX, Pontén F, Uhlén M, Jirström K, Nowis DA, Crown JP, Zagozdzon R, Gallagher WM.

Breast Cancer Res. 2014 Jul 10;16(4):R79. doi: 10.1186/bcr3691.

27.

The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.

Abdul-Jalil KI, Sheehan KM, Toomey S, Schmid J, Prehn J, O'Grady A, Cummins R, O'Neill B, McNamara DA, Deasy J, Breathnach O, Grogan L, Rogers A, Doherty G, Winter D, Ryan J, El-Masry S, Gibbons D, Sheahan K, Gillen P, Kay EW, Hennessy BT.

Ann Surg Oncol. 2014 Aug;21(8):2642-9. doi: 10.1245/s10434-014-3658-x. Epub 2014 Apr 4.

PMID:
24700299
28.

PARP Inhibitors as P-glyoprotein Substrates.

Lawlor D, Martin P, Busschots S, Thery J, O'Leary JJ, Hennessy BT, Stordal B.

J Pharm Sci. 2014 Jun;103(6):1913-20. doi: 10.1002/jps.23952. Epub 2014 Apr 3.

PMID:
24700236
29.

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.

BMC Cancer. 2014 Feb 22;14:120. doi: 10.1186/1471-2407-14-120.

30.

BAYESIAN SPARSE GRAPHICAL MODELS FOR CLASSIFICATION WITH APPLICATION TO PROTEIN EXPRESSION DATA.

Baladandayuthapani V, Talluri R, Ji Y, Coombes KR, Lu Y, Hennessy BT, Davies MA, Mallick BK.

Ann Appl Stat. 2014;8(3):1443-1468.

31.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

32.

Increased platelet reactivity in patients with late-stage metastatic cancer.

Cooke NM, Egan K, McFadden S, Grogan L, Breathnach OS, O'Leary J, Hennessy BT, Kenny D.

Cancer Med. 2013 Aug;2(4):564-70. doi: 10.1002/cam4.86. Epub 2013 May 21.

33.

The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.

Abdul-Jalil KI, Sheehan KM, Kehoe J, Cummins R, O'Grady A, McNamara DA, Deasy J, Breathnach O, Grogan L, O'Neill BD, Faul C, Parker I, Kay EW, Hennessy BT, Gillen P.

Colorectal Dis. 2014 Jan;16(1):O16-25. doi: 10.1111/codi.12439.

PMID:
24119076
34.

Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis.

Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, Kennedy S, Clynes M.

Carcinogenesis. 2013 Oct;34(10):2300-8. doi: 10.1093/carcin/bgt208. Epub 2013 Jun 5.

PMID:
23740839
35.

Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins.

Myhre S, Lingjærde OC, Hennessy BT, Aure MR, Carey MS, Alsner J, Tramm T, Overgaard J, Mills GB, Børresen-Dale AL, Sørlie T.

Mol Oncol. 2013 Jun;7(3):704-18. doi: 10.1016/j.molonc.2013.02.018. Epub 2013 Mar 19.

36.

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT.

Mol Oncol. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007. Epub 2013 Jan 31.

37.

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS.

Ann Oncol. 2012 Dec;23(12):2997-3006. doi: 10.1093/annonc/mds586. Review.

PMID:
23166150
38.

Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer.

Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo A.

Breast Cancer Res. 2012 Oct 26;14(5):R138. doi: 10.1186/bcr3343.

39.

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.

Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS.

Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9.

40.

Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.

Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB.

Genome Res. 2012 Nov;22(11):2120-9. doi: 10.1101/gr.137596.112. Epub 2012 Oct 1.

41.

An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays.

Guo H, Liu W, Ju Z, Tamboli P, Jonasch E, Mills GB, Lu Y, Hennessy BT, Tsavachidou D.

Proteome Sci. 2012 Sep 24;10(1):56. doi: 10.1186/1477-5956-10-56.

42.

Mechanistic basis for overcoming platinum resistance using copper chelating agents.

Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT.

Mol Cancer Ther. 2012 Nov;11(11):2483-94. doi: 10.1158/1535-7163.MCT-12-0580. Epub 2012 Aug 21.

43.

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.

Mohd Sharial MS, Crown J, Hennessy BT.

Ann Oncol. 2012 Dec;23(12):3007-16. doi: 10.1093/annonc/mds200. Epub 2012 Aug 2. Review.

44.

Management of unusual histological types of breast cancer.

Cadoo KA, McArdle O, O'Shea AM, Power CP, Hennessy BT.

Oncologist. 2012;17(9):1135-45. Epub 2012 Jul 23. Review.

45.

Network inference using steady-state data and Goldbeter-Koshland kinetics. [corrected].

Oates CJ, Hennessy BT, Lu Y, Mills GB, Mukherjee S.

Bioinformatics. 2012 Sep 15;28(18):2342-8. doi: 10.1093/bioinformatics/bts459. Epub 2012 Jul 19. Erratum in: Bioinformatics. 2013 Mar 15;29(6):819.

46.

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.

Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB.

Gynecol Oncol. 2012 Jul;126(1):47-53. doi: 10.1016/j.ygyno.2012.04.006. Epub 2012 Apr 6.

47.

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.

Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, Broaddus RR.

Mod Pathol. 2012 May;25(5):699-708. doi: 10.1038/modpathol.2011.208. Epub 2012 Feb 3.

48.

Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer.

Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, Lim JY, Li J, Lu Y, Gonzalez-Angulo AM, Jeong W, Mills GB, Safe S, Lee JS.

EMBO Mol Med. 2012 Jan;4(1):52-67. doi: 10.1002/emmm.201100187. Epub 2011 Dec 15.

49.

Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.

Wang LE, Ma H, Hale KS, Yin M, Meyer LA, Liu H, Li J, Lu KH, Hennessy BT, Li X, Spitz MR, Wei Q, Mills GB.

J Cancer Res Clin Oncol. 2012 Mar;138(3):377-85. doi: 10.1007/s00432-011-1103-0. Epub 2011 Dec 7.

50.

Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest.

Russell P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T, Venkitaraman AR.

Oncogene. 2012 May 10;31(19):2450-60. doi: 10.1038/onc.2011.431. Epub 2011 Nov 7.

Supplemental Content

Loading ...
Support Center